But agency says it cannot definitively rule out a like to blood clots
- Remains important to keep track of all side effects
- Will continue to study possible links to blood clots
This is not the definitive kind of 'this is safe' ruling we'd all like.
This is not the definitive kind of 'this is safe' ruling we'd all like.
Most Popular
BYD's new luxury EV boasts 5-min charging & 500-mile range, challenging Tesla's EV dominance.
Bitcoin's war-linked selloff shrinks; it's outperforming S&P 500, Nasdaq & gold. Risk appetite returns.
Broadcom's AI vision sparks debate: Nvidia rival or overvalued bet? Investors weigh $100B potential vs. risks.
Oil prices surge to $120, risking inflation & slowing growth. Fed faces stagflation fears, unlike 1973.
MELI's 47% revenue growth vs. AMZN's 24% AWS growth. MELI trades at 27x EV/EBIT, AMZN similar. MELI's margin compression vs. AMZN's expansion.
AVGO eyes $3T club with 91% upside potential. Strong AI demand fuels 29% revenue growth & low PEG ratio.
BYD's new EV boasts 5-min flash charging & 500-mile range, challenging luxury rivals. Valuation to watch!
Must Read